CCM
Consonance Capital Management Portfolio holdings
AUM
$7.28M
This Quarter Return
-9.33%
1 Year Return
-42.86%
3 Year Return
+319.33%
5 Year Return
+899.35%
10 Year Return
–
AUM
$661M
AUM Growth
+$661M
(-11%)
Cap. Flow
+$43M
Cap. Flow
% of AUM
6.51%
Top 10 Holdings %
Top 10 Hldgs %
76.63%
Holding
30
New
8
Increased
5
Reduced
6
Closed
8
Top Buys
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
$62.1M |
| 2 |
Ironwood Pharmaceuticals
IRWD
|
$54.1M |
| 3 |
MACK
Merrimack Pharmaceuticals, Inc.
MACK
|
$49.2M |
| 4 |
NUVA
NuVasive, Inc.
NUVA
|
$48.9M |
| 5 |
Assertio
ASRT
|
$38.4M |
Top Sells
| 1 |
INSY
Insys Therapeutics, Inc.
INSY
|
$73.5M |
| 2 |
AKRX
Akorn, Inc.
AKRX
|
$70.7M |
| 3 |
LCI
Lannett Company, Inc.
LCI
|
$52.8M |
| 4 |
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
|
$28.8M |
| 5 |
OSIR
Osiris Therapeutics, Inc. Common Stock
OSIR
|
$23.3M |
Sector Composition
| 1 | Healthcare | 90.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MNK
1
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $68M | 10.29% | 1,110,000 +350,000 | +46% | +$21.4M |
|
2
Orthofix Medical
OFIX
$592M
| $62.5M | 9.46% | 1,505,896 -343,500 | -19% | -$14.3M |
|
|
MDVN
3
DELISTED
MEDIVATION, INC.
MDVN
| $62.1M | 9.39% | +1,350,000 | New | +$62.1M |
|
|
4
Ironwood Pharmaceuticals
IRWD
$214M
| $54.1M | 8.18% | +4,944,139 | New | +$54.1M |
|
|
MACK
5
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $49.2M | 7.44% | +5,875,171 | New | +$49.2M |
|
|
NUVA
6
DELISTED
NuVasive, Inc.
NUVA
| $48.9M | 7.4% | +1,005,000 | New | +$48.9M |
|
7
AbbVie
ABBV
$372B
| $47.6M | 7.2% | 833,000 +55,000 | +7% | +$3.14M |
|
8
Pacific Biosciences
PACB
$393M
| $38.4M | 5.81% | 4,517,517 -981,195 | -18% | -$8.34M |
|
|
9
Assertio
ASRT
$80.4M
| $38.4M | 5.81% | +2,756,360 | New | +$38.4M |
|
10
Travere Therapeutics
TVTX
$1.56B
| $37.3M | 5.64% | 2,729,947 -730,376 | -21% | -$9.98M |
|
|
ARIA
11
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $35.6M | 5.39% | +5,575,742 | New | +$35.6M |
|
12
ANI Pharmaceuticals
ANIP
$2.03B
| $34.6M | 5.24% | 1,028,364 +81,875 | +9% | +$2.76M |
|
|
EGRX
13
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $28.1M | 4.25% | 693,937 -712,200 | -51% | -$28.8M |
|
|
AGN
14
DELISTED
Allergan plc
AGN
| $25.5M | 3.85% | +95,000 | New | +$25.5M |
|
15
Vericel Corp
VCEL
$1.83B
| $13.1M | 1.98% | 2,232,940 -120,000 | -5% | -$703K |
|
16
ADMA Biologics
ADMA
$4.12B
| $8.58M | 1.3% | 1,060,017 | – | – |
|
|
SPNE
17
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $2.45M | 0.37% | 167,298 +19,575 | +13% | +$287K |
|
18
Axogen
AXGN
$743M
| $2.18M | 0.33% | 406,351 | – | – |
|
19
Penumbra
PEN
$10.6B
| $1.84M | 0.28% | +40,000 | New | +$1.84M |
|
|
BIOL
20
DELISTED
Biolase, Inc.
BIOL
| $1.64M | 0.25% | 1,253,292 +157,200 | +14% | +$206K |
|
21
Veracyte
VCYT
$2.39B
| $895K | 0.14% | 165,825 | – | – |
|
|
DSCI
22
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $5K | ﹤0.01% | 181,818 -755,698 | -81% | -$20.8K |
|
23
Catalyst Pharmaceutical
CPRX
$2.52B
| – | – | -2,888,942 | Closed | -$7.08M |
|
24
Vanda Pharmaceuticals
VNDA
$279M
| – | – | -1,093,696 | Closed | -$10.2M |
|
|
LCI
25
DELISTED
Lannett Company, Inc.
LCI
| – | – | -1,316,700 | Closed | -$52.8M |
|